Paradox is focused on the development of treatment for immunoglobulin light chain amyloidosis (AL amyloidosis), a complication of multiple myeloma that can lead to heart, kidney and liver failure ...
Paradox Immunotherapeutics ("Paradox"), a pharmaceutical company focused on the development of innovative antibody therapies that treat protein misfolding diseases, today announced a $10 million ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback